Document is current

Article History

Received: 4 July 2023

Accepted: 27 September 2023

First Online: 15 October 2023

Declarations

:

: Assessments based on the AMSP database have been approved by the Ethics Committee of the University of Munich and the Ethics Committee of the Hannover Medical School (Nr. 8100_BO_S_2018). This study adheres to the Declaration of Helsinki and its later amendments. The AMSP program is a continuous observational post-marketing drug surveillance program and does not interfere with the ongoing clinical treatment of the patients under surveillance (see Methods: Data source).

: Not applicable.

: G. Hasler has received honoraria from Lundbeck, Servier, Takeda, Otsuka, Schwabe, Janssen, Sunovion, Vifor, Desitin Pharma, Sanofi, Recordati.K. Cattapan has received honoraria from Zeller Medical, Lundbeck, Om-Pharma, Janssen, Mepha.A. Erfurth has received lectures and/or Advisory Boards for Angelini, Boehringer Ingelheim, Germania, Idorsia, Janssen, Lundbeck, Mylan, Neuraxpharm, Recordati and Sandoz.S. Bleich and S. Toto are project managers of the AMSP program.S. Toto is a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker's honoraria from Janssen-Cilag, Lundbeck/Otsuka, Recordati Pharma GmbH, and Servier.J. Seifert has taken part in educational events sponsored by Otsuka/Lundbeck.G. Schoretsanitis has served as a consultant for Dexcel Pharma, HLS Therapeutics, Saladax and Thermo Fisher and has received speaker's fees from HLS Therapeutics.All other authors state they have no conflicts of interest to declare.